Skip to main content
Category

Uncategorized

Bioengineering against the most resistant and deadly bacterial infections

An international team, led by Profs Giuseppe Battaglia and Loris Rizzello from the Institute for Bioengineering of Catalonia (IBEC) at the Barcelona Science Park, carried out out a study that opens the door to a new therapy capable of quickly and effectively eliminating infections caused by intracellular bacteria, the most resistant to immune defenses. This therapy, based on synthetic vesicles, could considerably reduce the dose and duration of antimicrobial treatments, thus reducing the danger of generating resistance to antibiotics of pathogens such as those leading to tuberculosis.

 

Read More

Vesismin introduces the Ultraviolet Germicidal Irradiation in leading hospitals

The company Vesismin Health –present in the Barcelona Science Park and specialized in the development and commercialization of products for the control of infections in hospital environments– has introduced the advanced UVGI technology (Ultraviolet Germicidal Irradiation), in different hospitals in Spain. Its professional system for medical use, UV-360, produces germicidal ultraviolet radiation for comprehensive disinfection of rooms and is equipped with motion sensors that automatically interrupt operation when they detect a presence.

 

Read More

Promoting scientific careers in times of COVID-19

Against the backdrop of the major challenges posed by the COVID-19 pandemic, which has underscored the crucial role science and technology play in our society, the Barcelona Science Park is stepping up its commitment to persuading young people to choose scientific careers by holding a new edition of Batx2Lab, a pioneering programme which has inspired the STEM talent of more than 700 young people.

 

Read More

Ona Therapeutics raises €30M in Series A financing

Ona Therapeutics –a spin-off from IRB Barcelona and ICREA, based in the Barcelona Science Park– announces today the closing of a €30 million Series A financing, the largest private funding round closed for a start-up in Spain. The financing will allow Ona Therapeutics to complete the pre-clinical development in a variety of tumor types and to move its lead candidate into first clinical studies in patients with metastatic cancer in 2023.

 

Read More

Christophe Deluz wins the PCB artistic contest

The artistic contest for realizing an exterior mural at Barcelona Science Park has a winner: Christophe Deluz, with “Cachalote” (Sperm Whale), a huge and very colorful artwork, full of dynamism, that will decorate an exterior space of the Cluster II building, accessible to all users of PCB. That was the members of the jury decision, gathered on the 11th of June, after studying 18 candidacies.

 

Read More

Gorka Etxebarria, new Chief Scientific Officer of Nostrum Biodiscovery

Nostrum Biodiscovery (NBD) has appointed Dr. Gorka Etxebarria as new Chief Scientific Officer. Dr Etxebarria has a solid career linked to drug discovery projects in the pharmaceutical industry. His incorporation comes after the signing of Ezequiel Mas as new company CEO, to pilot a new stage of growth as a global provider of leading molecular simulation technologies applied to drug discovery and design.

 

Read More

Oxolife raises €5 million in a funding round and joins the Barcelona Science Park

The biotech Oxolife –focused on the development of a new treatment to improve the female fertility rate– has moved its headquarters to the Barcelona Science Park. The company, which has just raised a €5 million funding round, will start a phase II clinical trial to evaluate the efficacy of OXO-001, a drug that specifically acts on embryo implantation to increase pregnancy success rate in assisted reproductive technology processes.

 

Read More